Cancer pharmacogenomics
Cancer Pharmacogenomics
Cancer Pharmacogenomics (pronunciation: /ˈkænsər ˌfɑːrməkoʊdʒɪˈnoʊmɪks/) is a branch of Pharmacogenomics that focuses on the role of the genome in drug response in cancer treatment.
Etymology
The term "Cancer Pharmacogenomics" is derived from three words: "Cancer", a disease caused by an uncontrolled division of abnormal cells in a part of the body; "Pharma", a prefix derived from the Greek word "pharmakon" meaning drug; and "Genomics", a discipline in genetics that applies recombinant DNA, DNA sequencing methods, and bioinformatics to sequence, assemble, and analyze the function and structure of genomes.
Overview
Cancer Pharmacogenomics aims to develop effective, safe medications and doses that will be tailored to a person's genetic makeup. It is a rapidly growing field that has the potential to significantly improve the efficacy and safety of cancer treatment. The main goal of cancer pharmacogenomics is to identify genetic variants that predict drug response or toxicity, which can be used to guide drug selection and dosing.
Related Terms
- Pharmacogenetics: The study of inherited genetic differences in drug metabolic pathways which can affect individual responses to drugs, both in terms of therapeutic effect as well as adverse effects.
- Genome: The complete set of genes or genetic material present in a cell or organism.
- Genetic Variant: A difference in the DNA sequence in the genome from the normal sequence.
- Toxicity: The degree to which a substance can harm humans or animals.
See Also
External links
- Medical encyclopedia article on Cancer pharmacogenomics
- Wikipedia's article - Cancer pharmacogenomics
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski